Entero Therapeutics Research and Development Expenses 2015-2024 | ENTO

Entero Therapeutics research and development expenses from 2015 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Entero Therapeutics Research and Development Expenses 2015-2024 | ENTO

Entero Therapeutics research and development expenses from 2015 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$119.5B
Regeneron Pharmaceuticals (REGN)$114.6B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$101.6B
CSL (CSLLY)$97.4B
GSK (GSK)$84.8B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.4B
Biogen (BIIB)$28.2B
BioNTech SE (BNTX)$28B
Moderna (MRNA)$24.6B
Illumina (ILMN)$21.1B
BeiGene (BGNE)$20.7B
Genmab (GMAB)$16B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.6B
Incyte (INCY)$12.5B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$12.4B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.6B
Roivant Sciences (ROIV)$8.6B
Legend Biotech (LEGN)$8.5B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$7.7B
Exelixis (EXEL)$7.5B